Caren van Roekel

142 Chapter 5 TABLE 1. Baseline and treatment characteristics (continued) Characteristic N (%) or median with range 90 Y-resin 90 Y-glass 166 Ho No extrahepatic disease Extrahepatic disease at baseline Total Irinotecan 26 (57) 9 (45) 10 (42) 23 (48) 22 (52) 45 (50) Oxaliplatin 40 (87) 17 (85) 23 (96) 41 (85) 39 (93) 80 (89) Paclitaxel 0 (0) 0 (0) 1 (4) 0 (0) 1 (1) 1 (1) Panitumumab 8 (17) 4 (20) 3 (13) 9 (19) 6 (14) 15 (17) 5-FU 7 (15) 3 (15) 5 (21) 7 (15) 8 (19) 15 (17) Previous locoregional treatment Yes 17 (37) 7 (35) 6 (25) 17 (35) 13 (31) 30 (33) No 29 (63) 13 (65) 18 (75) 31 (65) 29 (69) 60 (67) Metastasis pattern Synchronous 31 (67) 15 (75) 15 (63) 27 (56) 34 (81) 61 (68) Metachronous 15 (33) 5 (25) 9 (37) 21 (44) 8 (19) 29 (32) Time since diagnosis (months) 25 (3-97) 24 (11-110) 26 (6-92) 26 (3-110) 21 (5-92) 25 (3-110) Time since diagnosis of metastatic disease (months) 17 (3-72) 23 (2-50) 18 (2-92) 17 (2-54) 21 (5-92) 19 (2-92) KRAS status Wildtype 16 (35) 8 (40) 9 (37) 21 (44) 12 (29) 33 (37) Mutation 11 (24) 3 (15) 6 (26) 7 (15) 13 (31) 20 (22) Unknown 19 (41) 9 (45) 9 (37) 10 (21) 17 (40) 37 (41) CEA level 72 (3-2700) 68 (3-640) 100 (2-6000) 61 (2-2700) 115 (3-6000) 88 (2-6000)